Key challenges in the use & development of digital endpoints from a health technology assessment (HTA) perspective

Digital endpoints offer a great potential to be considered in the HTA framework. So far, however, there is no institutional way in.  On February 15, 2021, IMI Neuronet hosted an online meeting of its working group on health technology assessment (HTA) and regulatory interactions, moderated by Diana O’Rourke from the National Institute for Health and Care Excellence (NICE). The discussions were based around the experiences of three different IMI projects that are…

IMI article about our Digital Health Catalyst initiative

The Digital Health Catalyst (DHC) was created by Mobilise-D and IDEA-FAST in response to the growing need for research and application in the area of real-world digital measurements. “The field will require a new generation of personnel from areas including clinical research and application, sensor and hardware development, infrastructure and data handling, data processing and…

EMA Public Support for Mobilise-D

In the first year of Mobilise-D, we asked the European Medicines Agency (EMA) for qualification advice for Digital Mobility Outcomes (DMOs). EMA just published their letter of support that publicly endorses our initial stage in the wider objective of the Mobilise-D Consortium to pursue the qualification of Digital Mobility Outcomes (DMOs) as monitoring biomarkers of…